Unichem Laboratories Share Price
Sector: Major Drugs
616.10 -3.50 (-0.56%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
613.20
Today’s High
626.35
52 Week Low
507.20
52 Week High
949.85
618.00 +0.85 (0.14%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
610.40
Today’s High
626.80
52 Week Low
501.00
52 Week High
937.95
Key Metrics
- Market Cap (In Cr) 4379.4
- Beta 0.84
- Div. Yield (%) 0
- P/B 1.84
- TTM P/E -
- Peg Ratio -
- Sector P/E 26.62
- Open Price 613.2
- Prev Close 619.6
Unichem Laboratories Analysis
Price Analysis
-
1 Week0.52%
-
3 Months-15.52%
-
6 Month-19.39%
-
YTD-17.02%
-
1 Year6.32%
Risk Meter
- 40% Low risk
- 40% Moderate risk
- 40% Balanced Risk
- 40% High risk
- 40% Extreme risk
Unichem Laboratories News
Stock market today: Experts recommend five stocks to buy or sell on Wednesday
5 min read . 23 Oct 2024Unichem Laboratories Q1 results : profit at ₹9.26Cr, Revenue increased by 5.49% YoY
1 min read . 09 Aug 2024Unichem Laboratories Q3 FY24 results: profit at ₹83.99Cr, Revenue increased by 43.6% YoY
1 min read . 07 Feb 2024Unichem Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1704.89
- Selling/ General/ Admin Expenses Total
- 832.88
- Depreciation/ Amortization
- 113.24
- Total Operating Expense
- 1778.72
- Operating Income
- -73.83
- Net Income Before Taxes
- -61.67
- Net Income
- -70.47
- Diluted Normalized EPS
- -4.84
- Period
- 2024
- Total Assets
- 3169.34
- Total Liabilities
- 806.93
- Total Equity
- 2362.42
- Tangible Book Valueper Share Common Eq
- 335.32
- Period
- 2024
- Cashfrom Operating Activities
- 16.69
- Cashfrom Investing Activities
- 50.4
- Cashfrom Financing Activities
- -106.31
- Net Changein Cash
- -32.84
- Period
- 2023
- Total Revenue
- 1343.02
- Selling/ General/ Admin Expenses Total
- 711.99
- Depreciation/ Amortization
- 113.44
- Total Operating Expense
- 1535.57
- Operating Income
- -192.54
- Net Income Before Taxes
- -176.36
- Net Income
- -202.23
- Diluted Normalized EPS
- -25.43
- Period
- 2023
- Total Assets
- 3193.05
- Total Liabilities
- 757.74
- Total Equity
- 2435.3
- Tangible Book Valueper Share Common Eq
- 345.68
- Period
- 2023
- Cashfrom Operating Activities
- -48.71
- Cashfrom Investing Activities
- 202.81
- Cashfrom Financing Activities
- -81.3
- Net Changein Cash
- 74.56
- Period
- 2022
- Total Revenue
- 1269.83
- Selling/ General/ Admin Expenses Total
- 670.98
- Depreciation/ Amortization
- 91.17
- Total Operating Expense
- 1283.1
- Operating Income
- -13.27
- Net Income Before Taxes
- 21.97
- Net Income
- 33.06
- Diluted Normalized EPS
- 4.92
- Period
- 2022
- Total Assets
- 3318.77
- Total Liabilities
- 700.36
- Total Equity
- 2618.41
- Tangible Book Valueper Share Common Eq
- 371.68
- Period
- 2022
- Cashfrom Operating Activities
- -259.61
- Cashfrom Investing Activities
- 102.4
- Cashfrom Financing Activities
- 191.23
- Net Changein Cash
- 31.74
- Period
- 2021
- Total Revenue
- 1235.14
- Selling/ General/ Admin Expenses Total
- 673.25
- Depreciation/ Amortization
- 84.36
- Total Operating Expense
- 1227.86
- Operating Income
- 7.28
- Net Income Before Taxes
- 51.48
- Net Income
- 34.32
- Diluted Normalized EPS
- 4.92
- Period
- 2021
- Total Assets
- 3125.71
- Total Liabilities
- 568.88
- Total Equity
- 2556.83
- Tangible Book Valueper Share Common Eq
- 362.94
- Period
- 2021
- Cashfrom Operating Activities
- 40.69
- Cashfrom Investing Activities
- -73.56
- Cashfrom Financing Activities
- -121.19
- Net Changein Cash
- -154.06
- Period
- 2020
- Total Revenue
- 1103.71
- Selling/ General/ Admin Expenses Total
- 670.21
- Depreciation/ Amortization
- 80.89
- Total Operating Expense
- 1234.73
- Operating Income
- -131.02
- Net Income Before Taxes
- -48.21
- Net Income
- -60.18
- Diluted Normalized EPS
- -8.34
- Period
- 2020
- Total Assets
- 3144.74
- Total Liabilities
- 613.38
- Total Equity
- 2531.35
- Tangible Book Valueper Share Common Eq
- 359.32
- Period
- 2020
- Cashfrom Operating Activities
- 132.68
- Cashfrom Investing Activities
- -35.91
- Cashfrom Financing Activities
- -62.3
- Net Changein Cash
- 34.47
- Period
- 2019
- Total Revenue
- 1180.05
- Selling/ General/ Admin Expenses Total
- 705.2
- Depreciation/ Amortization
- 67.37
- Total Operating Expense
- 1321.81
- Operating Income
- -141.77
- Net Income Before Taxes
- -59.91
- Net Income
- -23.8
- Diluted Normalized EPS
- -2.27
- Period
- 2019
- Total Assets
- 3149.61
- Total Liabilities
- 529.7
- Total Equity
- 2619.91
- Tangible Book Valueper Share Common Eq
- 371.98
- Period
- 2019
- Cashfrom Operating Activities
- -327.77
- Cashfrom Investing Activities
- -286.01
- Cashfrom Financing Activities
- -2.42
- Net Changein Cash
- -616.19
- Period
- 2018
- Total Revenue
- 814.98
- Selling/ General/ Admin Expenses Total
- 521.39
- Depreciation/ Amortization
- 50.51
- Total Operating Expense
- 993.15
- Operating Income
- -178.16
- Net Income Before Taxes
- -129.76
- Net Income
- 2544.91
- Diluted Normalized EPS
- -14.37
- Period
- 2018
- Total Assets
- 3193.67
- Total Liabilities
- 513.58
- Total Equity
- 2680.08
- Tangible Book Valueper Share Common Eq
- 380.75
- Period
- 2018
- Cashfrom Operating Activities
- -112.34
- Cashfrom Investing Activities
- 1648.33
- Cashfrom Financing Activities
- -881.13
- Net Changein Cash
- 654.86
- Period
- 2024-12-31
- Total Revenue
- 533.09
- Selling/ General/ Admin Expenses Total
- 101.74
- Depreciation/ Amortization
- 30.54
- Other Operating Expenses Total
- 154.31
- Total Operating Expense
- 478.11
- Operating Income
- 54.98
- Net Income Before Taxes
- 61.85
- Net Income
- 57.85
- Diluted Normalized EPS
- 8.19
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 462.16
- Selling/ General/ Admin Expenses Total
- 98.81
- Depreciation/ Amortization
- 28.54
- Other Operating Expenses Total
- 131.34
- Total Operating Expense
- 433.17
- Operating Income
- 28.99
- Net Income Before Taxes
- 32.99
- Net Income
- 30.49
- Diluted Normalized EPS
- 4.32
- Period
- 2024-09-30
- Total Assets
- 3310.96
- Total Liabilities
- 910.31
- Total Equity
- 2400.65
- Tangible Book Valueper Share Common Eq
- 340.75
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 44.83
- Cashfrom Investing Activities
- -46.45
- Cashfrom Financing Activities
- 37.87
- Net Changein Cash
- 36.87
- Period
- 2024-06-30
- Total Revenue
- 446.43
- Selling/ General/ Admin Expenses Total
- 98.49
- Depreciation/ Amortization
- 28.33
- Other Operating Expenses Total
- 143.87
- Total Operating Expense
- 431.26
- Operating Income
- 15.17
- Net Income Before Taxes
- 15
- Net Income
- 9.26
- Diluted Normalized EPS
- 1.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 431.7
- Selling/ General/ Admin Expenses Total
- 99.42
- Depreciation/ Amortization
- 27.16
- Other Operating Expenses Total
- 140.04
- Total Operating Expense
- 559.13
- Operating Income
- -127.43
- Net Income Before Taxes
- -125.87
- Net Income
- -129.31
- Diluted Normalized EPS
- -6.76
- Period
- 2024-03-31
- Total Assets
- 3169.34
- Total Liabilities
- 806.93
- Total Equity
- 2362.42
- Tangible Book Valueper Share Common Eq
- 335.32
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 16.69
- Cashfrom Investing Activities
- 50.4
- Cashfrom Financing Activities
- -106.31
- Net Changein Cash
- -32.84
- Period
- 2023-12-31
- Total Revenue
- 434.38
- Selling/ General/ Admin Expenses Total
- 98.11
- Depreciation/ Amortization
- 27.86
- Other Operating Expenses Total
- 131.66
- Total Operating Expense
- 359.33
- Operating Income
- 75.05
- Net Income Before Taxes
- 83.97
- Net Income
- 83.99
- Diluted Normalized EPS
- 5.65
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 415.63
- Selling/ General/ Admin Expenses Total
- 96.72
- Depreciation/ Amortization
- 29.45
- Other Operating Expenses Total
- 147.34
- Total Operating Expense
- 436.32
- Operating Income
- -20.69
- Net Income Before Taxes
- -21.88
- Net Income
- -24.49
- Diluted Normalized EPS
- -3.48
- Period
- 2023-09-30
- Total Assets
- 3069.93
- Total Liabilities
- 661.92
- Total Equity
- 2408.01
- Tangible Book Valueper Share Common Eq
- 341.8
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -77.58
- Cashfrom Investing Activities
- -8.79
- Cashfrom Financing Activities
- -36.67
- Net Changein Cash
- -120.61
- Period
- 2023-06-30
- Total Revenue
- 423.19
- Selling/ General/ Admin Expenses Total
- 98.81
- Depreciation/ Amortization
- 28.77
- Other Operating Expenses Total
- 127.92
- Total Operating Expense
- 423.94
- Operating Income
- -0.75
- Net Income Before Taxes
- 2.12
- Net Income
- -0.67
- Diluted Normalized EPS
- -0.09
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 402.1
- Selling/ General/ Admin Expenses Total
- 88.73
- Depreciation/ Amortization
- 29.68
- Other Operating Expenses Total
- 121.84
- Total Operating Expense
- 448.84
- Operating Income
- -46.74
- Net Income Before Taxes
- -47.16
- Net Income
- -44.27
- Diluted Normalized EPS
- -3.03
- Period
- 2023-03-31
- Total Assets
- 3193.05
- Total Liabilities
- 757.74
- Total Equity
- 2435.3
- Tangible Book Valueper Share Common Eq
- 345.68
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -48.71
- Cashfrom Investing Activities
- 202.81
- Cashfrom Financing Activities
- -81.3
- Net Changein Cash
- 74.56
- Period
- 2022-12-31
- Total Revenue
- 302.5
- Selling/ General/ Admin Expenses Total
- 90.57
- Depreciation/ Amortization
- 30.78
- Other Operating Expenses Total
- 116.3
- Total Operating Expense
- 376.04
- Operating Income
- -73.54
- Net Income Before Taxes
- -61.28
- Net Income
- -63.93
- Diluted Normalized EPS
- -9.03
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Unichem Laboratories Technical
Moving Average
SMA
- 5 Day635.72
- 10 Day614.94
- 20 Day642.03
- 50 Day658.83
- 100 Day698.74
- 300 Day678.83
Unichem Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Pfizer
- 4267.9
- 21.8
- 0.51
- 6452.85
- 3742.9
- 19526.05
- Neuland Laboratories
- 12570.65
- 270.05
- 2.2
- 18089.55
- 5557
- 16064.79
- Unichem Laboratories
- 616.1
- -3.5
- -0.56
- 949.85
- 507.2
- 4379.4
- Jagsonpal Pharmaceuticals
- 233.2
- -10.35
- -4.25
- 328.02
- 109.42
- 1548.42
- Themis Medicare
- 131.3
- -2
- -1.5
- 313.65
- 115.05
- 1215.78
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Pfizer
- 35.49
- 5.41
- 18.43
- 24.05
- Neuland Laboratories
- 49.57
- 12.3
- 14.98
- 11.99
- Unichem Laboratories
- -
- 1.84
- -2.1
- -3.99
- Jagsonpal Pharmaceuticals
- 71.13
- 8.5
- 13.79
- 9.21
- Themis Medicare
- 28.29
- 3.25
- 18.03
- 14.96
Unichem Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 06-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 30-Sept-24
- Others
- 08-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 01-Nov-23
- Quarterly Results
- 14-Jul-23
- Quarterly Results
- 23-May-23
- Audited Results
- 06-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-24
- 28-Jun-24
- AGM
- 24-Mar-24
- 21-Feb-24
- POM
- 25-Sept-23
- 09-Aug-23
- AGM
- 05-May-23
- 03-Apr-23
- POM
- 09-Aug-22
- 28-Jun-22
- AGM
- 31-Jul-21
- 22-Jun-21
- AGM
- 29-May-21
- 27-Apr-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-22
- -
- 01-Aug-22
- 4
- 31-May-21
- -
- 22-Jul-21
- 4


